In line with these findings, the increased CD8+ T cell infiltration observed in our study suggests that MEL-dKLA may also synergize with immune checkpoint inhibitors, including anti-PD-1 or anti-CTLA-4 antibodies, in prostate cancer, thereby broadening its therapeutic potential. Here, CTLA4 is linked to prostate carcinoma.